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Objectives. We have previously reported a high prevalence of gluten-related serological markers (GRSM) in children and
young adults with cerebral palsy (CP). The majority had no enteropathy to suggest coeliac disease (CD). Antibodies against
transglutaminase 6 (anti-TG6) represent a new marker associated with gluten-related neurological dysfunction. The aim of this
studywas to investigate the prevalence of anti-TG6 antibodies in this group of individuals with an early neurological injury resulting
in CP.Materials and Methods. Sera from 96 patients with CP and 36 controls were analysed for IgA/IgG class anti-TG6 by ELISA.
Results. Anti-TG6 antibodies were found in 12/96 (13%) of patients with CP compared to 2/36 (6%) in controls. The tetraplegic
subgroup of CP had a significantly higher prevalence of anti-TG6 antibodies 6/17 (35%) compared to the other subgroups and
controls. There was no correlation of anti-TG6 autoantibodies with seropositivity to food proteins including gliadin. Conclusions.
An early brain insult and associated inflammation may predispose to future development of TG6 autoimmunity.
1. Introduction
Patients with cerebral palsy (CP) are characterized by abnor-
mal muscle tone, coordination problems, and delay in motor
development leading to difficulties in gait, balance, and
involuntary movements. Muscle spasticity is very common.
Associated conditions include epilepsy, dysarthria, cognitive
impairment, and feeding problems, which may result in
difficulties inweight gain and growth [1, 2] particularly for the
most severely affected CP groups (tetraplegic and dyskinetic
subgroups). The aetiology of the brain damage causing CP
is among others mainly hypoxia due to asphyxia leading to
ischemic brain injury. Another cause could be intrauterine
infection [3–5].
Since coeliac disease (CD) is a common cause of poor
growth, we previously analysed our cohort of CP patients for
IgA and IgG-antibodies against gliadin and transglutaminase
2 (TG2) and found a high prevalence of seropositive patients.
The highest prevalence was for IgG-AGA 36 and 61%, respec-
tively [6, 7] which is of low diagnostic value for CD [8].
The majority of these patients also did not have enteropathy
on routine histological or extended immunohistochemical
examination of small bowel biopsies [6, 9, 10]. However, a
number of patients tested positive for TG2 IgA (7/99) and/or
had circulating antibodies to deamidated gliadin peptides
(DGP; 7/40 tested), acceptedmarkers in CD diagnosis [6, 10].
The seropositive CP patients had a significantly lower weight,
height, and body mass index (BMI) and they were also more
severely handicapped, according to gross motor function
classification (GMFCS) [11].
Increasing numbers of studies have reported that gluten-
related disorders include extraintestinal manifestations, for
example, involving skin (dermatitis herpetiformis) and brain
(gluten Ataxia) [12–15]. Such manifestations may occur in
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the absence of overt gastrointestinal involvement and patients
may be seronegative for anti-TG2 IgA autoantibodies, the
commonly used diagnostic marker for CD [16].
TG2 is the autoantigen in CD, whilst TG3 is the autoanti-
gen in dermatitis herpetiformis, a blistering skin disease
with gluten-induced granular IgA-deposits in the papillary
dermis [12]. Another enzyme in the transglutaminase family
that is primarily expressed in the central nervous system is
transglutaminase 6 (TG6) [17]. We have demonstrated the
presence of circulating anti-TG6 antibodies in adults with
gluten Ataxia, independent of intestinal involvement [16].
This may suggest a bias of the immune response towards
different TG isozymes in extraintestinal manifestations (i.e.,
TG6 in gluten Ataxia and TG3 in dermatitis herpetiformis).
The aim of this study was to investigate the prevalence of
antibodies against TG6 in patients with CP.
2. Material and Methods
2.1. Participants
2.1.1. CP-Group. The study recruited 99 children and young
adults with CP living in the Swedish county council of
Va¨rmland and O¨rebro. In Sweden children and young adults
with CP are treated at specialized rehabilitation centers
where they can obtain specific support such as medical
care, physiotherapy, speech, occupational, and psychological
therapy until they have finished school. In some cases they
are 24 years of age before they are referred to the adult clinic.
There were 46 girls and 53 boys. At the time of enrolment
the age ranged from 18 months to 24 years (median age 11
years). There was no comorbidity for CD such as diabetes
mellitus or dermatitis herpetiformis at the time of inclusion.
Thediagnosis ofCP subgroupswas based on studies byMutch
et al. [18, 19]. A functional assessment of each child was
made on the basis of the GrossMotor Function Classification
System (GMFCS), graded I–V, where GMFCS V represent
the most severe disability [11]. Medical data of the CP-
group were reviewed retrospectively in medical files (RS).
Thirteen children had percutaneous gastrostomy (PEG) but
also received some gluten containing food orally. Eleven
children had treatment for gastroesophageal reflux disease
(GERD).
2.1.2. Controls. 36 children, aged 2–18 years (19 boys and 17
girls), were included in the serological analysis as controls.
These children had been investigatedwith laboratory analyses
for allergy but were found negative. No further clinical
information about the children was available.
2.2. Serology. Data on IgG and IgA AGA and TG2, DGP
antibodies and HLA testing were available from our previous
studies [6, 10] as well as the data of antibodies against dietary
proteins [7].
None in the CP-group had IgA deficiency (<0.07 g/L).
2.3. TG6 Antibody ELISA. Detection of antibodies to TG6
by ELISA followed our previously published protocol with
minor modifications [16]. Briefly, full-length human TG6
produced in SF9 cells was obtained from Zedira (Darmstadt,
Germany). Results with this antigen were comparable to
those obtained with recombinant TG6 produced in house in
E. coli (data not shown) [16]. TG6 was diluted to 2 𝜇g/mL
in 20mM Tris/HCl, 300mM NaCl, pH 7.6 immediately
prior to use and applied to high-capacity protein binding
96-well plates (Immulon 2HB; Thermo Electron, Waltham,
MA, USA) overnight at 4∘C. All subsequent incubations
were conducted at room temperature. Nonspecific binding
was blocked by incubation with 3% BSA (immunoassay
grade, Sigma 05477) in TBS (20mM Tris/HCl, pH 7.4,
150mM NaCl) for 1 h. Patient sera were diluted 1 : 100 in 1%
BSA in TBS and any protein aggregates present removed
by centrifugation at 10,000×g for 5min prior to being
applied to coated plates. All binding steps were carried
out for 90min and followed by five rinses with TBS/0.01%
Tween 20. Antibody binding was detected by incubation
with peroxidase-conjugated affinity purified anti-human IgA
(Jackson ImmunoResearch, West Grove, PA, USA; 109-
035-011, diluted 1 : 1000 in 1% BSA/TBS) or anti-human
IgG (Dako, Carpinteria, CA, USA; P0214, diluted 1 : 250 in
1% BSA/TBS). The reaction was finally developed for 2 h
using 5mM 5-amino-2-hydroxybenzoic acid/NaOH, pH 6.0,
0.005%H
2
O
2,
as a peroxidase substrate solution and stopped
by addition of an equal volume of lM NaOH to each well.
After 15 minutes, the absorbance at 490 nm was measured.
All serum samples were analysed in duplicate on wells
containing antigen or only BSA, included on the same plate.
The BSA only background was subtracted from values for
antigen. Units were calculated from a series of standards (0,
1, 3, 10, and 100U/mL; 1st generation assay) (Zedira) run
in parallel. Results are given as the mean of two indepen-
dent determinations. A measurement >14U/mL for IgA or
>34U/mL for IgG was considered positive. Thresholds were
set as the 98th percentile on a blood donor collective. As anti-
BSA antibodies may be prevalent in this patient cohort which
has enhanced immunity to dietary components [7] and this
may potentially impact on the analysis, we have evaluated
all samples also in a commercial assay without background
subtraction (Zedira).There was good agreement between the
results of the two ELISA methods (supplementary figure).
2.4. Ethics. The study was approved by Regional Ethical
Review Board in Uppsala. Participants or parents, as appro-
priate, gave written informed consent.
2.5. Statistical Analyses. All data were analyzed using the
Statistical Package for the Social sciences (SPSS) program,
version 15. Differences between groups were evaluated with
Pearson’s 𝜒2 test in cross tabulations and when appropriate
Fisher’s Exact Test. An independent t-test was used for body
mass index (BMI) (standard deviation, SD), height (SD), and
weight (SD), using 2-tailed significance.
𝑃 < 0.05 was considered significant.
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3. Results
3.1. Serological Analysis for Anti-TG6 Autoantibodies. Sera
from 96 patients with CP and 36 controls (children from
same geographical area) were available for analysis of autoan-
tibodies against TG6. We found elevated levels of anti-TG6
antibodies (IgG and/or IgA) in 12/96 (13%) in the CP-group
and 2/36 (6%) in the control group (𝑃 = 0.35). (Figure 1)
However, a positive test for TG6 antibodies was significantly
more frequent in the tetraplegic subgroup of CP, 6/17 (35%)
compared to the control group 6% (𝑃 = 0.01). We also found
statistical significance when the tetraplegic subgroup was
compared to the other CP subgroups (𝑃 = 0.006) (Figure 2).
IgA anti-TG6 antibodies were found in 7/96 (7%) compared
to 1/36 (3%) in the control group. (𝑃 = 0.45) IgG anti-TG6
antibodies were found in 6/96 (6%) compared to 1/36 (3%) in
the control group (𝑃 = 0.67). One child had elevated levels of
both IgA and IgG to TG6.
This CP cohort has been tested for CD as reported
previously. [6, 10] There was an association between anti-
TG6 antibodies and IgA antibodies to TG2 (𝑃 = 0.04) but
not for any of the other gluten-related serological markers
analysed (anti-TG2 IgG orAGA IgA/IgG) (Table 1(b)). Five of
the twelve patients with CP that tested positive for anti-TG6
antibodies were negative for all gluten-related serological
markers. Also, there was no correlation between anti-TG6
antibody titres and the presence of other indicators of CD
(Table 1(b)). Eleven of the twelve individuals with TG6
positivity had previously been tested for the coeliac HLA type
(DQB1 typing) and 6/11 were positive for HLA-DQ2 and/or
HLA-DQ8, and a further 2 carried one-half of the DQ2
heterodimer (DQ7, 𝛼5 subunit) which is known to confer
susceptibility to CD [21]. A further patient carries the rare
HLA-DQ9 which may also confer susceptibility according to
recent evidence [22].
3.2. Clinical Data of Patients Testing Positive for Anti-TG6
Antibodies. The clinical data of the 12 CP patients positive
for anti-TG6 antibodies are summarized in Table 1(a). The
median age was significantly higher in the TG6 positive
group, 14.4 years compared to 10.7 years in the TG6 negative
group (𝑃 = 0.021).
The majority was born at term (8/12) and had asphyxia.
Five had epilepsy-requiring medication.There was no signif-
icant difference in weight (𝑃 = 0.318) or BMI (𝑃 = 0.987)
between TG6 antibody positive and negative patients. There
was, however, a significant difference in height between the
2 groups. The children and young adults with CP positive for
anti-TG6were shorter (𝑃 = 0.021). As height correlates to the
degree of disability this may reflect a more severe disability,
consistent with a higher prevalence of anti-TG6 antibodies in
the tetraplegic subgroup [1].
Seven of these patients had previously been investigated
on clinical grounds using MRI or CT and the results were
reviewed as part of this study (NH). Brain malformation
was seen in one child and traumatic injury in another two.
Developmental malformations or defects as a consequence
of ischemia were seen in 3 cases. In one child with Ataxia
no significant abnormalities were found (Table 1(a)). As
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Figure 1: Analysis of serum for antibodies against transglutaminase
type 6 (TG6) by ELISA. Relative concentration of antibodies in
children (𝑛 = 96) with cerebral palsy (CP) and controls (𝑛 = 36)
is given in arbitrary units. Bolded line represents the mean titre of
the group and dotted line the threshold for a positive test.
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Figure 2: Percentage of patients testing positive for IgA/IgG
antibodies to TG6 in different CP subgroups and in a control group.
The tetraplegic subgroup compared to the other CP subgroups (𝑃 =
0.006) and to controls (𝑃 = 0.01); ∗𝑛 = 3missing for TG6 antibody
analysis. HP: CP-Hemiplegia, DP: CP-Diplegia, TP: CP-Tetraplegia,
DK: CP-Dyskinesia, and A: CP-Ataxia.
gastrointestinal dysfunction typically seen in the most severe
forms of CP may impact on gut permeability and lead to
enhanced immunity to food-derived antigens, we further
evaluatedwhether a correlation existed between TG6 autoan-
tibodies and indicators of feeding difficulties. There was no
significant difference for either the group that had treated
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Table 2: Correlation between indicators of feeding problems and immunity to TG6 and to AGA analysed previously (𝑛 = 99)∗ [6].
AGA positive 41/99∗
(41%)
AGA negative 58/99∗
(59%) 𝑃 value
TG6 antibody positive
12/96 (12.5%)
TG6
antibody
negative
84/96 (87.5%)
𝑃 value
Weight −1.960 SD −1.00 SD 𝑃 = 0.016 −1.917 SD −1.304 SD 𝑃 = 0.318
BMI −1.175 SD −0.136 SD 𝑃 = 0.006 −0.528 SD −0.537 SD 𝑃 = 0.987
PEG 𝑛 = 13 10/13 3/13 𝑃 = 0.005 2/13 11/13 𝑃 = 0.664
GERD 𝑛 = 11 6/11 5/11 𝑃 = 0.348 3/10Q 7/10Q 𝑃 = 0.111
∗90 children age < 18 year were published in the referred paper. Here we have calculated with the whole cohort, 𝑛 = 99, since we have the data available.
Q1 missing for analysis of TG6-antibodies.
SD: weight ± standard deviation (SD), also referred to as weight 𝑧-scores, standardized to the Swedish general population by age and sex and based on
3,650 healthy children [20]. GERD: gastroesophageal reflux disease; PEG: percutan endoscopic gastrostomy; AGA: IgA and IgG gliadin antibodies TG6:
transglutaminase 6.
GERDor assisted feeding (PEG)with regard to TG6 antibody
positivity (Table 2). In contrast, anti-gliadin antibodies previ-
ously identified [6] showed a strong associationwith PEG and
also correlated with patient weight and BMI (Table 2).
4. Discussions
The rational for the study was that anti-TG6 antibodies have
been described in the context of neurological manifestations
in gluten-related disorders andmay identify gluten sensitivity
in patients serologically negative for anti-TG2 antibodies
[23].
There was a significantly higher prevalence of TG6
antibodies in the subgroup of patients with the most severe
form of CP but not in the CP group as a whole. Furthermore,
a positive correlation of TG6 antibodies with TG2 IgA
antibodies but not to other antibodies tested is in keep-
ing with a shared/overlapping mechanistic origin of these
autoantibodies as has been suggested [24].
CP is a heterogeneous condition and is likely to have
a number of different causes. The most common cause is
an ischemic event in the immature brain. Bax et al. showed
that magnetic resonance imaging (MRI) abnormalities were
detectable in 88% of 351 children with CP [3]. The major
findings seen on MRI in the tetraplegic subgroup was white
matter damage of immaturity, including periventricular
leukomalacia (PVL) (35.1%) and to a lesser extent cortical
lesions. The finding of PVL was previously thought to be a
typical damage seen in premature-born children. However,
this neuroimaging study [3] has shown that white matter
damage can be a common finding also among term infants
and that in such cases the white matter loss tends to be more
extensive. The localisation and severity of the brain lesions
depend on the timing of the event in the immature brain and
differ between the subgroups of cerebral palsy [3] and so also
the clinical outcome of the lesion.
The weight is in general lower in the children with
CP compared to normal children and some children with
CP require food intake in an alternative way, that is, by
a percutaneous gastrostomy (PEG), to gain weight due to
their oral and gastrointestinal dysfunction. The most severe
forms of CP are in the subgroups of Dyskinesia (DK)
and Tetraplegia (TP). These patients also suffer most from
gastrointestinal disturbances and have the lowest weight gain
of the CP subgroups. In our recently published study from the
same cohort of patients, we found mainly IgG-antibodies not
only to gluten but also to other food proteins (lactoglobulin
and casein) in the DK and TP subgroups of CP who also
had the lowest weight [7]. It is likely that these patients
have increased intestinal permeability allowing entrance of
undigested proteins across the gut barrier into the circulation
[25] and therefore have enhanced immunity to food-derived
antigens. Such immune reactivity to dietary constituents has
also been reported in studies of underweight children from
underdeveloped countries [25, 26]. However, we could not
find a significant association between lower body weights or
the use of PEG and the presence of anti-TG6 autoantibodies;
in contrast, AGA antibodies significantly correlated with low
weight and assisted feeding (PEG).
There was a significantly higher prevalence of TG6
autoantibodies in the tetraplegic subgroup of patients com-
pared to controls and the other subgroups. In fact there was
no antibody response to TG6 in the other subgroup of CP
with severe deficiencies, the dyskinetic group. The reason for
that is not clear. One possibility could be that the type of
brain damage in the tetraplegic subgroup (extensive white
matter involvement) may predispose to future development
of an immune reaction against TG6. Indeed white matter
abnormalities on brainMR imaging are a common finding in
patients with CD and headaches [8, 27–30]. The hypothesis
of a primary brain insult leading to sensitisation to gluten
is supported by a recent study demonstrating increased
prevalence of CD in patients with previous head injury [31].
TGs are a family of structurally and functionally related
cross-linking enzymes. In mice, TG6 expression is associated
with neurogenesis in CNS development and in the mature
brain, in neurons in regions associated with motor function
including the cerebral cortex and cerebellum [17]. Antibodies
isolated from CD patients frequently react with human
and mouse neurons. Such antibodies are not the predom-
inant anti-TG2 IgA but either directed to TG6 or cross-
reactive between the closely related isozymes, TG2, TG3 and
TG6 [32]. Intraventricular injection of such patient-derived
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TG-specific immunoglobulins in mice induced Ataxia-like
deficits [32]. These data not only indicate that autoantibodies
to TG6 could be a marker of brain lesions but that such
antibodiesmay play a part in pathogenesis.The role of TG6 in
cerebellar functioning has recently been further highlighted
by the identification of mutations in the human gene encod-
ing TG6, causing autosomal dominant spinocerebellar Ataxia
[33, 34].
5. Conclusion
This study group of children with CP does not have a higher
prevalence of celiac disease than expected in the regional
population but they do havemore frequent immunoreactivity
to gluten and other dietary food components compared
to matched controls [6, 7]. Here, we report significantly
increased prevalence of anti-TG6 autoantibodies in the
tetraplegic subgroup of patients with CP. This antibody
response seems not to be correlated with low body weight
and the associated immune response to food constituents.
The aetiology of anti-TG6 antibodies in this CP subgroup
remains unclear, but the results could support the hypothesis
of a primary brain insult leading to TG6 autoimmunity.
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